Results 171 to 180 of about 4,107,997 (296)

Stock Market Valuation : the Role of the Macroeconomic Risk Premium [PDF]

Using annual and quarterly data since 1952, we estimate a fundamentals- based empirical model for the earning-price ratio of US stocks. The key fundamental-variable is a time-varying discount rate, decomposed into a time-varying measure for the real ...
Christophe Boucher
core  

Geographic authentication of premium tobacco extracts using machine learning models trained on LC-HRMS fingerprints. [PDF]

Front Mol Biosci
Xu XJ, Wang M, Li XP, Zhang WC, Zeng ST, Shi QZ, Ma YW, Lu BB, Liu S, Wang DZ, Wang RQ, Hu J.   +11 more
europepmc   +1 more source

Gut Health in Ostriches (Struthio camelus): Insights Into Intestinal Structure, Functions, Microbiome, and Improvement Strategies

Animal Research and One Health, EarlyView.
Our paper systematically reviews the intestinal structure, function, and microbiota of ostriches, along with strategies for improving their gut health. We analyze how these factors collectively influence intestinal homeostasis and ostrich welfare, emphasizing probiotics as a promising intervention to enhance gut health, boost population well‐being, and
Zi‐Qun Zhang, Fang‐Fang Guo, Wen‐Juan Du, Meng Li, Aftab Shaukat, Zhu‐Qing Jia, Shu‐Cheng Huang   +6 more
wiley   +1 more source

Market risk premium used in 2008: A survey of more than a 1,000 professors [PDF]

The average Market Risk Premium (MRP) used in 2008 by professors in the United States (6.5%) was higher than the one used by their colleagues in Europe (5.3%), Canada (5.4%), the United Kingdom (5.6%) and Australia (5.9%).
Fernandez, Pablo
core  

Impact of digital premium payment in scaling health insurance coverage in sub-Saharan Africa: systematic review and meta-analysis protocol. [PDF]

BMJ Open
Danso-Appiah A, Appiagyei N, Danso CA.
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Early community reactions and acceptance of the Sliding-Scale Community Based Health Insurance Scheme in Ethiopia: Qualitative Findings from the treatment arm. [PDF]

PLoS One
Birhanu Z, Gelana B, Berhanu N, Abdulbari S, Abdissa B, Abafita J, Chala BW, Sudhakar M, Abebe G, Andualem Y, Hailu H, Irena D, Haji H, Teferi T, Cantet N, Alzua ML.   +15 more
europepmc   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Variety-Seeking Behavior and Willingness to Pay for Staple Foods: Evidence from Online Food Delivery in China. [PDF]

Foods
Li M, Zhong F.
europepmc   +1 more source

Exposing the work of the market through the case of Alternative Provision for English school students

British Educational Research Journal, EarlyView.
Abstract Pupils in England who, for some reason, are not able to attend school often find themselves in Alternative Provision (AP). These are special arrangements designed to address their specific needs and help them return to mainstream schooling.
Nick Pratt, Elizabeth J. Done, Sam Morahan   +2 more
wiley   +1 more source